These findings collectively suggest that FZD2 promotes oncogenic phenotypes in gastric cancer, potentially through TGF-β-induced EMT, as supported by prior studies linking FZD2 to non-canonical Wnt signaling pathways. This evidence concerns the gene TGFB1 and gastric cancer.